1
|
Cruz-Aguilar DA, Hernández-Rodríguez M. Stereoselective synthesis of highly substituted 1-isomorphans (1-azabicyclo[3.3.1]nonanes). Chem Commun (Camb) 2023. [PMID: 37379083 DOI: 10.1039/d3cc00621b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/29/2023]
Abstract
We describe the first enantioselective synthesis of highly functionalized 1-azabicyclo[3.3.1]nonanes (1-IM). The 1-IM scaffold is present in natural products and drugs and is an isomer of the morphan moiety. The proposed methodology is based on an organocatalytic Michael addition of N-protected piperidine ketoesters to nitroalkenes and an intramolecular nitro-Mannich reaction as key transformations. The 1-IMs feature 6 contiguous stereocenters, substituents at positions 2 and 4, and nitro, ester, and hydroxyl functional groups at positions 3, 5, and 6 respectively. The synthesis is straightforward, highly stereoselective (up to 98% ee, >99 : 1 d.r.), with overall yields of up to 83% and requires only two purification steps.
Collapse
Affiliation(s)
- Diego A Cruz-Aguilar
- Instituto de Química, Universidad Nacional Autónoma de Mexico, Circuito Exterior, Ciudad Universitaria, Del. Coyoacán, Cd. Mx. 04510, Mexico.
| | - Marcos Hernández-Rodríguez
- Instituto de Química, Universidad Nacional Autónoma de Mexico, Circuito Exterior, Ciudad Universitaria, Del. Coyoacán, Cd. Mx. 04510, Mexico.
| |
Collapse
|
2
|
Nirogi R, Mohammed AR, Shinde AK, Bogaraju N, Gagginapalli SR, Ravella SR, Kota L, Bhyrapuneni G, Muddana NR, Benade V, Palacharla RC, Jayarajan P, Subramanian R, Goyal VK. Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. Eur J Med Chem 2015; 103:289-301. [PMID: 26363507 DOI: 10.1016/j.ejmech.2015.08.051] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Revised: 08/25/2015] [Accepted: 08/26/2015] [Indexed: 11/16/2022]
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease which has a higher prevalence and incidence in older people. The need for improved AD therapies is unmet. The 5-hydroxytryptamine4 receptor (5-HT4R) partial agonists may be of benefit for both the symptomatic and disease-modifying treatment of cognitive disorders associated with AD. Herein, we report the design, synthesis and SAR of imidazo[1,5-a] pyridine derivatives as 5-HT4R partial agonists. The focused SAR, optimization of ADME properties resulted the discovery of compound 5a as potent, selective, brain penetrant 5-HT4 partial agonist as a lead compound with good ADME properties and efficacy in both symptomatic and disease modifying animal models of cognition.
Collapse
Affiliation(s)
- Ramakrishna Nirogi
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India.
| | - Abdul Rasheed Mohammed
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Anil K Shinde
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Narsimha Bogaraju
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Shankar Reddy Gagginapalli
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Srinivasa Rao Ravella
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Laxman Kota
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Gopinadh Bhyrapuneni
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Nageswara Rao Muddana
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Vijay Benade
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Raghava Chowdary Palacharla
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Pradeep Jayarajan
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Ramkumar Subramanian
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Vinod Kumar Goyal
- Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| |
Collapse
|
3
|
Ngo AN, El Kassimi K, Amara Z, Drège E, Joseph D. Amine-mediated tandem conjugative isomerization-bridging Michael addition: concise synthesis of 1-azabicyclo[3.3.1]nonanes. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.04.069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Wojciechowska-Nowak M, Boczoń W, Warżajtis B, Rychlewska U, Jasiewicz B. Thioanalogues of N-1-methylanabasine and nicotine – Synthesis and structure. J Mol Struct 2011. [DOI: 10.1016/j.molstruc.2011.01.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Borsini E, Broggini G, Colombo F, Khansaa M, Fasana A, Galli S, Passarella D, Riva E, Riva S. Enantiopure 2-piperidylacetaldehyde as a useful building block in the diversity-oriented synthesis of polycyclic piperidine derivatives. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.tetasy.2011.01.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Abele E, Abele R, Golomba L, Višņevska J, Beresneva T, Rubina K, Lukevics E. Oximes of six-membered heterocyclic compounds with two and three heteroatoms. II.* Reactions and biological activity (review). Chem Heterocycl Compd (N Y) 2010. [DOI: 10.1007/s10593-010-0602-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RAL, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JAM, Turner SD, Vickery RG. A Multivalent Approach to the Design and Discovery of Orally Efficacious 5-HT4 Receptor Agonists. J Med Chem 2009; 52:5330-43. [DOI: 10.1021/jm900881j] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- R. Murray McKinnell
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Scott R. Armstrong
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - David T. Beattie
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Seok-Ki Choi
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Paul R. Fatheree
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Roland A. L. Gendron
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Adam Goldblum
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Patrick P. Humphrey
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Daniel D. Long
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Daniel G. Marquess
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - J. P. Shaw
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Jacqueline A. M. Smith
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - S. Derek Turner
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| | - Ross G. Vickery
- Department of Medicinal Chemistry
- Department of Pharmacology
- Department of Drug Metabolism and Pharmacokinetics
- Department of Molecular and Cellular Biology
- Theravance, Inc., 901 Gateway Boulevard, South San Francisco, California 94080
| |
Collapse
|
8
|
Fish PV, Mackenny M, Bish G, Buxton T, Cave R, Drouard D, Hoople D, Jessiman A, Miller D, Pasquinet C, Patel B, Reeves K, Ryckmans T, Skerten M, Wakenhut F. Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2008.11.025] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Scarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs 2008; 17:1663-70. [DOI: 10.1517/13543784.17.11.1663] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
10
|
Meyers NL, Hickling RI. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D 2008; 9:37-63. [PMID: 18095752 DOI: 10.2165/00126839-200809010-00004] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Renzapride (ATL-1251), a novel benzamide, is currently under clinical development for the treatment of irritable bowel syndrome (IBS). Previous in vitro and in vivo experimental studies have characterized renzapride as a full serotonin 5-HT(4) receptor agonist on the gut and a 5-HT(3) receptor antagonist. Clinical studies have confirmed the therapeutic efficacy, tolerability and safety of renzapride in patients with constipation-predominant IBS. This study set out to characterize the pharmacological profile of renzapride and its potential metabolic products at both 5-HT and other monoamine receptors in the gut. METHODS The affinity of renzapride, its (+) and (-) enantiomers, and its primary metabolite, renzapride N-oxide and its enantiomers, for serotonin receptors was assessed by means of in vitro radioligand binding inhibition studies. After membranes prepared from animal tissue or membranes of cell lines transfected with cloned human receptors had been incubated with radiolabelled ligand with high affinity for a specific receptor, renzapride was added to competitively inhibit this binding. Levels of bound radioligand were measured by filtration and counting of the bound radioactivity. In instances where >50% inhibition of radioligand binding had occurred, the inhibition constant (K(i)) was calculated. Metabolism of renzapride by liver microsomes was assessed by incubating 10 micromol/L renzapride with human liver microsome samples for 60 minutes at 37 degrees C. After the reaction was stopped, the samples were centrifuged and the supernatant analysed for metabolites by high-pressure liquid chromatography (HPLC). The potential inhibitory effects of renzapride on cytochrome P450 (CYP) enzymes were assessed by incubating renzapride at various concentrations over a 1-500 micromol/L concentration range with microsomes genetically engineered to express a single CYP. RESULTS Renzapride was selective for serotonergic receptors and, in particular, had high affinity for human 5-HT(3) and guinea-pig 5-HT(4) receptors (K(i) 17 and 477 nm, respectively). Inhibitory properties at 5-HT(2B) receptors were also identified for renzapride, as well as some affinity for 5-HT(2A) and 5-HT(2C) receptors. Renzapride N-oxide and its enantiomers demonstrated much lower affinity for all 5-HT receptors compared with renzapride. Renzapride was metabolized by liver microsomes to a limited extent and there was no significant non-microsomal metabolism of renzapride. Renzapride did not inhibit the major CYP drug-metabolizing enzymes CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2E1 or CYP3A4 at concentrations consistent with use in a clinical setting. CONCLUSIONS These results confirm and extend earlier studies in animal and human receptors that show renzapride is a potent and generally full 5-HT(4) receptor agonist and 5-HT(3) receptor antagonist. The results reported in the present study indicate that the metabolites of renzapride are minor and are unlikely to contribute to its therapeutic profile or lead to interaction of renzapride with other drugs that inhibit the major drug-metabolizing enzymes in the liver at therapeutic doses. These data contribute to the understanding of the pharmacological actions and metabolic fate of renzapride in vivo.
Collapse
|
11
|
Fish PV, Deur C, Gan X, Greene K, Hoople D, Mackenny M, Para KS, Reeves K, Ryckmans T, Stiff C, Stobie A, Wakenhut F, Whitlock GA. Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett 2008; 18:2562-6. [DOI: 10.1016/j.bmcl.2008.03.050] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2008] [Revised: 03/14/2008] [Accepted: 03/16/2008] [Indexed: 01/16/2023]
|
12
|
Zefirova ON, Zefirov NS. Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors. RUSSIAN CHEMICAL REVIEWS 2007. [DOI: 10.1070/rc2001v070n04abeh000654] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
13
|
Armstrong SR, McCullough JL, Beattie DT. Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat. J Pharmacol Toxicol Methods 2005; 53:198-205. [PMID: 16168678 DOI: 10.1016/j.vascn.2005.08.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2005] [Accepted: 08/14/2005] [Indexed: 01/07/2023]
Abstract
INTRODUCTION In vitro studies have demonstrated a 5-HT4 receptor-mediated relaxation of the pre-contracted rat esophagus. However, it is unclear whether 5-HT4 receptor agonists affect resting esophageal tone in vivo. The activity of 5-HT and several well-established 5-HT4 receptor agonists (tegaserod, BIMU-8, cisapride, renzapride, and mosapride) was investigated in a novel in vivo model designed to measure esophageal relaxation using the technique of digital sonomicrometry. METHODS Miniature piezo-electric crystals were implanted externally in a longitudinal orientation on the distal esophagus of isoflurane-anesthetized, adult male Sprague-Dawley rats. Measurement of the time for transmission of ultrasonic pulses between the implanted crystals provided a continuous recording of inter-crystal distance and hence esophageal muscle length. RESULTS Following cumulative intravenous administration, 5-HT (1-100 microg/kg), tegaserod (1-1000 microg/kg), BIMU-8 (3-3000 microg/kg), renzapride (10-3000 microg/kg), cisapride (30-3000 microg/kg), and mosapride (30-10,000 microg/kg) produced a dose-dependent increase in esophageal inter-crystal distance. The mean ED50 values for tegaserod, BIMU-8, renzapride, cisapride, and mosapride were 11, 49, 51, 141, and 1825 microg/kg, respectively. Pre-treatment with the selective 5-HT4 receptor antagonist, piboserod (SB-207266; 1 mg/kg subcutaneously) significantly attenuated the effects of intravenous tegaserod (1-1000 microg/kg). Following cumulative intraduodenal administration (0.03-10 mg/kg), tegaserod and mosapride exhibited a dose-dependent increase in esophageal inter-crystal distance. The doses associated with a 10% increase in muscle length from the resting level were 2.6 and>10 mg/kg for tegaserod and mosapride, respectively. DISCUSSION In conclusion, dose-dependent, 5-HT4 receptor agonist-mediated increases in longitudinal muscle length in the rat esophagus were observed in vivo using the technique of digital sonomicrometry. This in vivo model of esophageal activity may prove useful in evaluating the activity of novel 5-HT4 receptor agonists.
Collapse
Affiliation(s)
- Scott R Armstrong
- Pharmacology Laboratories, Theravance, Inc., 901 Gateway Blvd., South San Francisco, CA 94080, USA.
| | | | | |
Collapse
|
14
|
Hirokawa Y, Harada H, Yoshikawa T, Yoshida N, Kato S. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist. Chem Pharm Bull (Tokyo) 2002; 50:941-59. [PMID: 12130853 DOI: 10.1248/cpb.50.941] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In search of a dopamine D2 and serotonin 5-HT3 receptors dual antagonist as a potential broad antiemetic agent, a number of benzamides were prepared from 4-amino-5-chloro-2-methoxybenzoic acid derivatives and 6-amino-1,4-dialkylhexahydro-1,4-diazepines and evaluated for their binding affinity for the dopamine D2 and the serotonin 5-HT3 receptors using rat brain synaptic and rat cortical membranes, respectively. From the results of both in vitro receptor binding and in vivo biological assays for the dopamine D2 receptor, 1-ethyl-4-methylhexahydro-1,4-diazepine ring was selected as an optimum amine moiety. Introduction of one methyl group on the nitrogen atom at the 4-position and/or modification of the substituent at the 5-position of the 4-amino-5-chloro-2-methoxybenzoyl moiety caused a marked increase in the dopamine D2 receptor binding affinity along with a potent 5-HT3 receptor binding affinity. Among the compounds, 5-chloro-N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)-2-methoxy-4-methylaminobenzamide (82), 5-bromo (110), and 5-iodo (112) analogues exhibited a much higher affinity for the dopamine D2 receptor than that of metoclopramide (IC50=17.5-61.0 nM vs. 483 nM). In particular, 82 showed a potent antagonistic activity for both receptors in vivo tests. Optical resolution of the racemate 82 brought about a dramatic change in the pharmacological profile with the (R)-enantiomer exhibiting a strong affinity for both the dopamine D2 and the 5-HT3 receptors, while the corresponding (S)-enantiomer had a potent and selective serotonin 5-HT3 receptor binding affinity.
Collapse
Affiliation(s)
- Yoshimi Hirokawa
- Medicinal Chemistry Group, Chemistry Research Laboratories, Dainippon Pharmaceutical Co. Ltd, Suita, Osaka, Japan.
| | | | | | | | | |
Collapse
|
15
|
Harling JD, Harrington FP, Thompson M. A FACILE SYNTHESIS OF THE 3-AMINO-5,6,7,8-TETRAHYDRO[1,6]NAPHTHYRIDINE SYSTEM AND SOME ALKYLATED AND POLYCYCLIC HOMOLOGUES. SYNTHETIC COMMUN 2001. [DOI: 10.1081/scc-100103271] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
16
|
Combrink KD, Gulgeze HB, Yu KL, Pearce BC, Trehan AK, Wei J, Deshpande M, Krystal M, Torri A, Luo G, Cianci C, Danetz S, Tiley L, Meanwell NA. Salicylamide inhibitors of influenza virus fusion. Bioorg Med Chem Lett 2000; 10:1649-52. [PMID: 10937716 DOI: 10.1016/s0960-894x(00)00335-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay.
Collapse
Affiliation(s)
- K D Combrink
- Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 05492, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Knowles DJ, King F. The impact of bacterial genomics on antibacterial discovery. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1999; 456:183-95. [PMID: 10549369 DOI: 10.1007/978-1-4615-4897-3_10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Affiliation(s)
- D J Knowles
- SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK
| | | |
Collapse
|
18
|
Orjales A, Alonso-Cires L, López-Tudanca P, Tapia I, Mosquera R, Labeaga L. Benzimidazole-2-carboxylic acid amides and esters: a new structural class of 5-HT3 ligands. Eur J Med Chem 1999. [DOI: 10.1016/s0223-5234(99)80091-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Leclerc V, Fourmaintraux E, Depreux P, Lesieur D, Morgan P, Howell HE, Renard P, Caignard DH, Pfeiffer B, Delagrange P, Guardiola-Lemaître B, Andrieux J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. Bioorg Med Chem 1998; 6:1875-87. [PMID: 9839017 DOI: 10.1016/s0968-0896(98)00147-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A previous paper reported the synthesis of melatonin receptor ligands. In order to complete the structure-activity relationships and to obtain antagonists to the melatonin receptor, a new series of naphthalenic analogues of melatonin have been synthesized. Modifications include deletion of the 7-methoxy group, replacement of the ethylene moiety, replacement of the amidic function by bioisosteres, and replacement of the naphthalenic nucleus by other bicyclic rings. Almost all the structural modifications lead to decreased affinity for the melatonin receptor. However, the N-n propyl urea derivative (27) is a very potent ligand at this receptor (pKi = 14.3). Most interestingly deletion of the methoxy group resulted in the first antagonist in this series. This molecule, compound 12, or N-[2-(1-naphthyl)-ethyl]cyclobutyl carboxamide has been selected for preclinical development.
Collapse
Affiliation(s)
- V Leclerc
- Institut de Chimie Pharmaceutique, Lille, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Modulators of 5-HT functions in the treatment of Gastrointestinal Disorders. ACTA ACUST UNITED AC 1998. [DOI: 10.1016/s0165-7208(98)80056-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
21
|
Becker DP, Nosal R, Villamil CI, Gullikson G, Moummi C, Yang DC, Flynn DL. Serotonin 5-HT4 agonist activity of a series of meso-azanoradamantane benzamides. Bioorg Med Chem Lett 1997. [DOI: 10.1016/s0960-894x(97)00408-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Arias-Pérez MS, Alejo A, Maroto A. Structural study of 3-azabicyclo[3.3.1]nonane derivatives functionalized at 1 and/or 9-positions by molecular mechanics calculations and NMR spectroscopy. Tetrahedron 1997. [DOI: 10.1016/s0040-4020(97)00832-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Affiliation(s)
- L M Gaster
- SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, U.K
| | | |
Collapse
|
24
|
Affiliation(s)
- R. Freer
- Synthetic Isotope Chemistry Department, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, England
| | - S. Nash
- Synthetic Isotope Chemistry Department, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, England
| |
Collapse
|
25
|
Ramirez MJ, García-Garayoa E, Romero G, Monge A, Roca J, Del Río J, Lasheras B. VB20B7, a novel 5-HT-ergic agent with gastrokinetic activity. I. Interaction with 5-HT3 and 5-HT4 receptors. J Pharm Pharmacol 1997; 49:58-65. [PMID: 9120772 DOI: 10.1111/j.2042-7158.1997.tb06753.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
This study describes the in-vitro interaction of the gastrokinetic agent 2[1-(4-piperonyl)piperazinyl]benzothiazole (VB20B7) with the 5-hydroxytryptamine 5-HT3 and 5-HT4 receptor subtypes, using functional as well as radioligand binding studies. The benzamide derivative cisapride was used as a comparison. In radioligand binding assays VB20B7 showed, like cisapride, a weak affinity at 5-HT3 receptors from rat cerebral cortex. The new compound lacked any affinity at other 5-HT receptors or at dopaminergic D2 receptors, whereas cisapride showed high affinity for the 5-HT4 receptors from guinea-pig hippocampus and moderate affinity at dopaminergic D2 receptors. In the non-stimulated guinea-pig ileum, the concentration-response curves to the specific 5-HT3 agonist 2-Me-5-HT and to 5-HT were shifted to the right by VB20B7. In the rat oesophagus tunica muscularis mucosae preparation (TMM), VB20B7 was evaluated for its activity at 5-HT4 receptors. VB20B7 behaved as a 5-HT4 receptor agonist, inducing a concentration-dependent relaxation of the preparation precontracted with carbachol. In this preparation, VB20B7 and cisapride were able to stimulate adenylate cyclase activity, an effect probably mediated through activation of 5-HT4 receptors, as can be inferred from the blockade by the 5-HT4 antagonist, tropisetron, of the enhanced cAMP formation. However, consistent with the lack of affinity at central 5-HT4 receptors, VB20B7 did not stimulate cAMP formation in guinea-pig hippocampal slices. VB20B7 also caused an increase in the twitch response of the transmurally stimulated guinea-pig ileum, although at a concentration higher than cisapride. This effect was blocked by desensitization of the 5-HT4 receptor with 5-MeOT and also by the 5-HT4 receptor antagonist tropisetron. Both VB20B7 and cisapride increased the K(+)-evoked acetylcholine release in this preparation. The results show that VB20B7 possesses affinity for 5-HT4 receptors located in the rat TMM and guinea-pig ileum preparations, but is devoid of affinity at central 5-HT4 receptors. In addition, VB20B7 shows low to moderate affinity at both central and peripheral (enteric) 5-HT3 receptors. The interaction of VB20B7 with the peripheral 5-HT4 and 5-HT3 receptors may be relevant for the gastrokinetic effects of the new compound.
Collapse
Affiliation(s)
- M J Ramirez
- Department of Pharmacology, University of Navarra, Pamplona, Spain
| | | | | | | | | | | | | |
Collapse
|
26
|
|
27
|
|
28
|
Abstract
Recent, rapid progress in the molecular biology of serotonin (5-HT) receptors requires conceptual re-thinking with respect to receptor classification. Thus, based on operational criteria (agonist and antagonist rank order), as well as transduction mechanisms involved and the structure of the receptor protein, the Nomenclature Committee of the Serotonin Club has proposed the following classification and nomenclature: the main receptor types 5-HT1 to 5-HT4, recombinant receptors (e.g. 5-ht5 to 5-ht7) and 'orphan' receptors. The aim of the present review is to discuss the events leading to this classification, the criteria for and functional responses mediated by various 5-HT receptors, as well as the therapeutic possibilities with 5-HT ligands.
Collapse
Affiliation(s)
- P R Saxena
- Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, The Netherlands
| |
Collapse
|
29
|
Langlois M, Yang D, Brémont B, Shen S. Synthesis and pharmacological activity of a macrocyclic benzamide. Bioorg Med Chem Lett 1995. [DOI: 10.1016/0960-894x(95)00115-a] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
The synthesis, and dopamine D2 and serotonin 5-HT3 receptor affinity of 3-aza analogues (pyridyl) of 4-amino-5-chloro-2-methoxybenzamides. Bioorg Med Chem Lett 1995. [DOI: 10.1016/0960-894x(94)00453-m] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
31
|
|
32
|
Synthesis and conformational analysis of a bridged anabasine and related compounds. A nuclear magnetic resonance spectroscopy and molecular modeling study. Tetrahedron 1994. [DOI: 10.1016/s0040-4020(01)89606-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|